Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France
    Gentaur Germany

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA
    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Displaying items by tag: virus

    Researchers-revealed-the-way-for-success-in-gene-therapyScientists have found a new way to overcome one of the biggest obstacles to the use of viruses for therapeutic genes.
     
    Scientists from the Institute for research at national level have found a way to overcome one of the biggest obstacles to the use of viruses for administration of therapeutic genes, that is, how to prevent the immune system to neutralize the virus before it has delivered its genetic set.
     
    Gene therapy is one of the most promising possibilities for the treatment of genetic disorders such as muscular dystrophy, congenital blindness and hemophilia. Scientists explore gene therapy as a cure for certain types of cancer, neurodegenerative diseases, viral infections and other acquired diseases. In order to obtain a therapeutic gene into cells, scientists use viruses that deliver its genetic material in cells as part of their normal replication process.
     
    Again and again, these efforts were thwarted by the very immune system of the body that damages each viral vector. Thus the therapeutic gene can be delivered to diseased cells and disease raging in full force.
     
    A team led by Louis-Rodino Klapak, PhD, and Jerry Mendel, MD, principal investigator in the Center for Gene Therapy at Nationwide, show for the first time that using a process called plasmapheresis, just before delivery of the virus for gene therapy he is protected long enough to enter the cell and deliver their genetic material.
     
    In a study of gene therapy for the treatment of Duchenne muscular dystrophy (DMD), Dr. Rodino-Klapak using plasmapheresis in a large animal model, and then injected a virus carrying the gene micro-dystrophin. When studying the level of gene expression of the micro-dystrophin in animals, it was found that there is a 500% increase in the gene expression in the animals who received a plasmapheresis.
     
    Dr. Mendel believes that right now, gene therapy seems to work best in patients who have antibodies to the virus. It is this virus is used to supply the necessary gene. It is exactly this gene, which is a therapeutic, curative intent of the organism suffering from a disease. On the other hand, it limits the number of patients who can benefit from gene therapy. This is because in very few patients lacking antibodies against the virus.

    Using the method of plasmapheresis repeatedly increases the potential of gene therapy, as this eliminates the obstacle called immune response of the organism.
     
    As gene therapy becomes more widespread, it may be necessary, patients receiving more than one course of treatment.
     
    The main problem is that when you go home after the first treatment, their body develops antibodies to the virus used to deliver the therapeutic gene. The use of plasma in a patient who previously received gene therapy may allow him to be treated again.

    Published in News
    Tuesday, 29 July 2014 16:58

    Discovery of a new intestinal virus

    gentaur-new-virusScientists have discovered a previously unknown virus that lives in the human gut, according to a study published in Nature Communications.
     
    An international team of scientists discovered the virus in CrAssphage genetic material from samples of intestine. Scientists believe the virus can affect the behavior of some of the most common bacteria in the intestinal flora.
     
    Experts explain that these types of viruses called bacteriophages play an important role in chronic diseases. Leading a team from the State University at San Diego, USA, "clears" the genetic information that is stored in three large international databases.
     
    They fall on the portion of the DNA to be detected in more than half of all the samples. Further analysis found that the virus has not been detected so far.
     
    Scientists explain that it has a genetic fingerprint of the bacteriophage - type virus, which is known to infect the bacteria. He can control the behavior of bacteria that affect - in some cases makes it easier to live in the environment in which they are located, and may make the bacteria more powerful.
     
    Scientists are trying to grow the virus in the laboratory. Explain that the next step will be to establish exactly the way in which the virus affects intestinal bacteria.

    Published in News

    Gentaur proteinProtein in the body can improve its ability to detect and treat viral infections such as influenza and hepatitis C. This conclusion leads a laboratory study by researchers from the University Institute of cancer in Pittsburgh, USA.
     
    To start playback in the body, the virus actually "invaded" cells and "takes" control over them.
     
    Experts explain that, despite progress in the field of vaccines and treatment diseases caused by viral infections remain among the leading causes of death in the world. According to them, there is a need for a new type of security and the new discovery appears to be promising for further studies.
     
    Scientists isolated protein of similar oligoadenylate synthetase-occurring in humans, suffering from liver cancer, prichinen of hepatitis C. When the Expert increase the levels of this protein in human cells, observed inhibition of virus replication.
     
    In later study found that murine organisms in which there is no presence of the protein are susceptible to a large extent of a viral infection, in comparison to those who have it.

    Viruses affect the ribonucleic acid (RNA), including hepatitis C, influenza and respiratory syncytial virus, using RNA as the genetic material, when played back.
     
    The types of treatment, based on the protein like oligoadenylate synthetase, can enhance the ability of cells to detect RNA, used by the virus, and thus to activate the immune system to stop its reproduction.

    Published in News
    Thursday, 10 April 2014 10:33

    Tobacco plants are struggling with virus

    Tobacco plants are struggling with virusInternational research group led by Professor Chen has developed a new generation of potentially safer and more cost-effective therapies against West Nile virus etc, and other pathogens.

    Scientists applied therapy based on monoclonal antibodies and their derivatives.

    For the purposes of the study monoclonal antibodies are derived from tobacco plants, which is promising to change the image of the plant, which are believed to cause cancer of the lung.

    The antibodies are directed against proteins located on the surface of the virus.

    The main objective of the study is to create innovative, sustainable and affordable therapy that also be a cheap solution to combat the global threat of West Nile virus.

    One approach is the development of therapeutic antibodies that bind to receptors which may help of the monoclonal antibodies to cross into the brain.

    In a new study, the researchers developed a half-dozen new options that could assist in the implementation monoclonal antibodies that can be effectively targeted to the brain and to neutralize the dangerous virus.

    The final results of the study show 90% success in preventing letalnit development in experimental conditions.

    This is the first case of such an effect, leading to the neutralization of the virus.

    Dr. Chen results are motivating the development of plant-based therapy that dramatically reduce the cost of commercial production of monoclonal antibodies.

    The virus is spread by infected mosquitoes and affect the central nervous system.

    Infection can cause serious, life-altering and even fatal disease.

    Until now, however, is not available or effective drug therapy for dealing with infection.

    Published in News
    Thursday, 17 October 2013 12:35

    Avian Influenza Virus Detection Using Smell

    influenza-virus-gentaur-antibodiesNew research from the Monell Chemical Senses Center and the U.S. Department of Agriculture (USDA) reveals how diseases can modify animal odors in subtle ways. In a recent study published in the public access journal PLOS ONE, scientists examined how infection with avian influenza (AIV) alters fecal odors in mallards.

    Using both behavioral and chemical methods, the findings reveal that AIV can be detected based on odor changes in infected birds.

    "The fact that a distinctive fecal odor is emitted from infected ducks suggests that avian influenza infection in mallards may be 'advertised' to other members of the population," notes Bruce Kimball, PhD, a research chemist with the USDA National Wildlife Research Center (NWRC) stationed at the Monell Center. "Whether this chemical communication benefits non-infected birds by warning them to stay away from sick ducks or if it benefits the pathogen by increasing the attractiveness of the infected individual to other birds, is unknown."

    In the study, laboratory mice were trained to discriminate between feces from AIV-infected and non-infected ducks, indicating a change in odor. Chemical analysis then identified the chemical compounds associated with the odor changes as acetoin and 1-octen-3-ol.

    The same compounds also have been identified as potential biomarkers for diagnosing gastrointestinal diseases in humans. Kimball and colleagues hypothesize that metabolites resulting from viral infection interact in concert with bacteria in the gastro-intestinal system of ducks to produce "odor signatures" indicating presence of the AI virus.

    "Avian influenzas are typically asymptomatic in ducks and waterfowl. Infection in these species can only be diagnosed by directly detecting the virus, requiring capture of birds and collection of swab samples. Our results suggest that rapid and simple detection of influenzas in waterfowl populations may be possible through exploiting this odor change phenomenon," said Monell behavioral biologist Gary Beauchamp, PhD, also an author on the paper.

    Future work will assess whether odor changes can be used for surveillance of AIV in waterfowl. In particular, researchers are interested in whether the odor change is specific to the AIV pathogen or if it is merely a general response to a variety of pathogens normally found in birds. Other studies will explore communicative functions of the AIV odor to gain greater understanding of how odors can shape social behavior in wildlife populations.

    Also contributing to the research, which was funded by the National Wildlife Research Center, were Kunio Yamazaki and Maryanne Opiekun of Monell and Richard Bowen and Jack Muth from Colorado State University. Dr. Yamazaki, who actively contributed to the design and realization of this work, died in April 2103.

    Published in News

    bottles-gentaur-antibodiesPRODUCT DESCRIPTION:
    Influenza viruses are enveloped viruses with a diameter of 80-120 nm, and contain a singlestranded, segmented, negative-sense RNA within a nucleocapsid. Influenza virus is propagated in the MDCK cell line. Influenza Culture Fluid is sold in 1.0 mL aliquots, and is shipped on dry ice. Viral culture fluids consist of virus, cells, and media taken directly from the tissue culture flask. Each lot of viral culture fluid is assayed for its Tissue Culture Infective Dose (TCID50), and sold with titers >105 U/ml. Custom orders are available, including specific titers and package sizes.

    INTENDED USE:
    This product is intended for research, product development testing, or quality assurance testing. Viral culture fluids are sold as consumable testing materials, and are not for propagation or commercialization. Applications include:
    - Nucleic Acid / Molecular Testing
    - Limit of Detection (LOD) Studies
    - Cross-reactivity Studies
    - Other Viral-based Assays

    TIOLOGIC STATUS/BIOHAZARD TESTING:
    Influenza virus is a Biosafety Level 2 organism.


    PRECAUTIONS:
    USE UNIVERSAL PRECAUTIONS when handling this product! Viral Culture Fluid is live and infectious!! This material should be handled as if capable of transmitting infectious agents.

    RECOMMENDED STORAGE:
    Viral culture fluid is stable for at least one year when stored at -65ºC or below. To avoid repeat freeze-thaws, which could negatively impact product performance, culture fluid should be stored in aliquots upon receipt.


    DO NOT USE IN HUMANS!
    These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act, or for any other product intended for administration to humans.

    Order Button1

    Published in Promos

    bottles-gentaur-antibodiesPRODUCT DESCRIPTION:
    Influenza viruses are enveloped viruses with a diameter of 80-120 nm, and contain a singlestranded, segmented, negative-sense RNA within a nucleocapsid. Influenza virus is propagated in the MDCK cell line. Influenza Culture Fluid is sold in 1.0 mL aliquots, and is shipped on dry ice. Viral culture fluids consist of virus, cells, and media taken directly from the tissue culture flask. Each lot of viral culture fluid is assayed for its Tissue Culture Infective Dose (TCID50), and sold with titers >105 U/ml. Custom orders are available, including specific titers and package sizes.


    INTENDED USE:
    This product is intended for research, product development testing, or quality assurance testing. Viral culture fluids are sold as consumable testing materials, and are not for propagation or commercialization. Applications include:
    - Nucleic Acid / Molecular Testing
    - Limit of Detection (LOD) Studies
    - Cross-reactivity Studies
    - Other Viral-based Assays

    TIOLOGIC STATUS/BIOHAZARD TESTING:
    Influenza virus is a Biosafety Level 2 organism.

    PRECAUTIONS:
    USE UNIVERSAL PRECAUTIONS when handling this product! Viral Culture Fluid is live and infectious!! This material should be handled as if capable of transmitting infectious agents.

    RECOMMENDED STORAGE:
    Viral culture fluid is stable for at least one year when stored at -65ºC or below. To avoid repeat freeze-thaws, which could negatively impact product performance, culture fluid should be stored in aliquots upon receipt.
    DO NOT USE IN HUMANS!
    These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act, or for any other product intended for administration to humans.

    Order Button1

    Published in Promos

    bottles-gentaur-antibodiesPRODUCT DESCRIPTION:
    Influenza viruses are enveloped viruses with a diameter of 80-120 nm, and contain a singlestranded, segmented, negative-sense RNA within a nucleocapsid. Influenza virus is propagated in the MDCK cell line. Influenza Culture Fluid is sold in 1.0 mL aliquots, and is shipped on dry ice. Viral culture fluids consist of virus, cells, and media taken directly from the tissue culture flask. Each lot of viral culture fluid is assayed for its Tissue Culture Infective Dose (TCID50), and sold with titers >105 U/ml. Custom orders are available, including specific titers and package sizes.


    INTENDED USE:
    This product is intended for research, product development testing, or quality assurance testing. Viral culture fluids are sold as consumable testing materials, and are not for propagation or commercialization. Applications include:
    - Nucleic Acid / Molecular Testing
    - Limit of Detection (LOD) Studies
    - Cross-reactivity Studies
    - Other Viral-based Assays

    TIOLOGIC STATUS/BIOHAZARD TESTING:
    Influenza virus is a Biosafety Level 2 organism. 

    PRECAUTIONS:
    USE UNIVERSAL PRECAUTIONS when handling this product! Viral Culture Fluid is live and infectious!! This material should be handled as if capable of transmitting infectious agents.


    RECOMMENDED STORAGE:
    Viral culture fluid is stable for at least one year when stored at -65ºC or below. To avoid repeat freeze-thaws, which could negatively impact product performance, culture fluid should be stored in aliquots upon receipt.
    DO NOT USE IN HUMANS!
    These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act, or for any other product intended for administration to humans.

    Order Button1

    Published in Promos

    bottles-gentaur-antibodiesPRODUCT DESCRIPTION:
    Influenza viruses are enveloped viruses with a diameter of 80-120 nm, and contain a singlestranded, segmented, negative-sense RNA within a nucleocapsid. Influenza virus is propagated in the MDCK cell line. Influenza Culture Fluid is sold in 1.0 mL aliquots, and is shipped on dry ice. Viral culture fluids consist of virus, cells, and media taken directly from the tissue culture flask. Each lot of viral culture fluid is assayed for its Tissue Culture Infective Dose (TCID50), and sold with titers>105 U/ml. Custom orders are available, including specific titersand package sizes.


    INTENDED USE:
    This product is intended for research, product development testing, or quality assurance testing. Viral culture fluids are sold as consumable testing materials, and are not for propagation or commercialization. Applications include:
    - Nucleic Acid / Molecular Testing
    - Limit of Detection (LOD) Studies
    - Cross-reactivity Studies
    - Other Viral-based Assays

    TIOLOGIC STATUS/BIOHAZARD TESTING:
    Influenza virus is a Biosafety Level 2 organism.

    PRECAUTIONS:
    USE UNIVERSAL PRECAUTIONS when handling this product! Viral Culture Fluid is live and infectious!! This material should be handled as if capable of transmitting infectious agents.

    RECOMMENDED STORAGE:
    Viral culture fluid is stable for at least one year when stored at -65ºC or below. To avoid repeat freeze-thaws, which could negatively impact product performance, culture fluid should be stored in aliquots upon receipt.
    DO NOT USE IN HUMANS!
    These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act, or for any other product intended for administration to humans.

    Order Button1

    Published in Promos